Learn the clinical science, treatment experience, and patient outcomes of Ketamine therapy.
Ketamine affects NMDA receptors and glutamate signaling. Studies have examined changes in depressive symptoms, but mechanisms are still being investigated and benefits are not guaranteed.
IV ketamine delivers the medicine directly into the bloodstream with clinical monitoring. Its use for psychiatric disorders is off-label, and the evidence, risks and alternatives should be discussed during your evaluation.
At Resova, we offer intravenous (IV) ketamine and Spravato (esketamine nasal spray). They have different approval status, dosing and monitoring requirements. Your clinician can explain which options may be appropriate for your condition and treatment history.
Research is exploring how ketamine affects synaptic plasticity and depressive symptoms. Much of the work on brain connections comes from laboratory and animal studies; it does not establish permanent repair of damaged synapses in patients.
A consultation at our Fairfax clinic reviews your diagnosis, previous care and treatment goals. Evidence differs across depression, other psychiatric conditions and chronic pain. A diagnosis alone does not establish that ketamine is appropriate or that treatment will help.
Infusions take place in our private, quiet suites with clinical monitoring. Monitoring helps the team identify and respond to adverse effects; it does not eliminate risk. We coordinate care with your existing providers as appropriate.
"It is just a temporary party drug"
Clinical ketamine treatment uses a prescription medicine under medical supervision. The dose and monitoring depend on the treatment plan; psychiatric use is off-label and carries risks.
Outcomes and the time to benefit vary. Ketamine is not a substitute for emergency care when there is immediate danger.
Ketamine affects NMDA receptors and glutamate signaling. These mechanisms do not establish that treatment repairs brain connections in patients.
IV ketamine and Spravato have different evidence, approval status and monitoring requirements. Coverage depends on your plan.
An initial IV ketamine course may involve six sessions over 2–3 weeks. Your clinician determines the schedule and whether further treatment is appropriate based on benefits and adverse effects. Spravato follows a different dosing schedule.
Clinical Prep: Patients are evaluated by our medical team. On the day of your infusion, you will relax in a private, low-stimulus suite equipped with noise-canceling headphones, eye masks, and a comfortable medical recliner.
Clinical Monitoring: Monitoring is part of the treatment visit. IV ketamine and Spravato follow different protocols; Spravato requires supervised administration and monitoring for at least two hours, followed by assessment of whether you are ready to leave.
The Infusion Experience: As the low-dose ketamine is administered, most patients describe a feeling of deep relaxation, a floating sensation, or mild, dream-like dissociation. Our rooms are fully optimized for comfort, allowing you to recline in peace while our clinical team checks on you regularly.
Recovery and Discharge: Discharge depends on your clinical condition, not a fixed promise that all effects resolve within two hours. Arrange a driver home. After Spravato, do not drive until the next day after restful sleep; follow your care team’s instructions for IV ketamine.
Follow your care team’s food and drink instructions for the specific treatment. IV ketamine and Spravato preparation requirements differ.
Review all medicines with your care team and prescribing clinician. Do not stop or change prescribed medication on your own.
The need for further infusions and their timing depend on your response, adverse effects and ongoing clinical assessment.
Ketamine is not FDA-approved to treat psychiatric disorders. Discuss its off-label use, alternatives and uncertainties with your clinician.
A response reported in a study does not predict your individual outcome. The amount and duration of benefit can vary, and some people do not improve. Follow-up decisions should consider benefit, adverse effects and your goals.
Risks: Ketamine can cause sedation, dissociation, breathing problems and increased blood pressure. Misuse or abuse and urinary or bladder symptoms are also concerns. Clinical supervision does not eliminate risk.
Recovery: Ask about monitoring, discharge criteria, transport and when to resume activities. Do not assume that every person recovers within a fixed number of minutes.
Ongoing care: Discuss whether further treatment is appropriate and how benefit and adverse effects would be assessed. Do not change prescribed medicines without consulting the prescribing clinician.
FDA ketamine safety communication (archived)
Ask how your medical history and current medicines affect suitability.
Discuss the monitoring and discharge process with your care team.
Agree on transport, activity instructions and a follow-up plan.
Previous treatment, symptoms, medical history and individual risks are considered together. A diagnosis or a particular number of treatment attempts does not automatically make someone a candidate.
A consultation can review major depressive disorder (MDD) or other diagnosed conditions, previous treatment and medical history. Psychiatric ketamine use is off-label; the evidence and risks differ by condition.
During the initial consultation, Dr. Arora reviews your medical and psychiatric history, current medicines and potential risks. Screening helps determine whether a treatment is appropriate; it cannot guarantee safety.
Coordinated Care: We work with your referring psychiatrist, counselor or primary care provider to review relevant records and coordinate an appropriate care plan.
Ongoing Evaluations: Follow-up considers changes in symptoms, adverse effects and your goals. Continuing treatment depends on clinical assessment and your individual experience.
Diagnosis, previous treatment, medical history and risks are reviewed together. Eligibility is not automatic.
Discuss cardiovascular and psychiatric history, current medicines and treatment-specific contraindications with your clinician.
We coordinate updates directly with your primary therapist or psychiatrist.
Clinical trials have studied symptom changes after ketamine and esketamine. Benefits, risks and durability vary; research findings do not guarantee an individual result.
Ketamine acts on N-methyl-D-aspartate (NMDA) receptors and affects glutamate signaling. Researchers are studying how these effects relate to synaptic plasticity and changes in depressive symptoms. Mechanistic research includes animal studies and does not establish permanent repair of brain connections in patients.[6]
Zarate and colleagues (2006) studied 18 participants in a small placebo-controlled crossover trial. Depression scores improved after a single ketamine infusion, with differences measured from 110 minutes. The short follow-up and small sample do not establish lasting remission or predict an individual response.[1]
Murrough and colleagues (2013) followed 24 participants receiving up to six ketamine infusions in an open-label study. Symptoms improved during treatment, but relapse occurred after the course; the study did not include a control group.[3] Shiroma and colleagues (2020) compared repeated with single ketamine treatment over 12 days. Most, but not all, measured cognitive functions were stable or improved. These findings do not establish an absence of cognitive risk or long-term safety.[5]
Popova and colleagues (2019) compared esketamine nasal spray plus a newly started oral antidepressant with placebo nasal spray plus a newly started oral antidepressant over four weeks in adults with treatment-resistant depression. Depression scores favored esketamine at the primary endpoint; adverse effects and treatment discontinuations also occurred.[2] McIntyre and colleagues (2021) provide expert guidance on evidence, safety, monitoring and clinical implementation, while identifying remaining uncertainties.[4]
FDA APPROVAL & MILESTONES
Ketamine was initially approved as an anesthetic. Its use for psychiatric conditions remains off-label.
A small randomized trial found rapid changes in depression scores after one infusion; it did not establish that a single infusion resolves depression for everyone.[1]
Spravato nasal spray was approved for treatment-resistant depression in adults, initially in conjunction with an oral antidepressant.
The indication expanded to depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, with an oral antidepressant. Effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been established.[7]
Laboratory findings help researchers study possible mechanisms; they do not prove permanent brain repair in an individual patient.
Trial populations, response definitions and follow-up periods differ. Results from one study cannot guarantee remission or durable benefit.
We offer transparent package pricing, interest-free financing, and direct insurance billing support for Spravato sessions.
IV Ketamine Infusions: Because psychiatric IV ketamine remains off-label, infusions are generally self-pay at $397 per infusion for mood and addiction protocols ($1,197 per infusion for pain protocols). We offer a 6-infusion series at $1,985, one infusion free with the purchase of 5 ($5,985 for the pain series). The initial consult evaluation may be billed to your health insurance.
Spravato (Esketamine): As an FDA-approved treatment, Spravato may be covered by major insurance plans (including Aetna, Anthem BCBS, Cigna, United Healthcare and TRICARE), depending on your plan; not every plan covers it, and prior authorization is required. Covered patients typically pay standard specialist co-pays after meeting deductibles.
Financing: We partner with CareCredit and M-Lend to offer flexible, interest-free monthly financing options to ensure treatment is affordable. HSA/FSA cards are accepted for all treatments.
We provide full superbills with appropriate CPT modifiers for out-of-network reimbursement requests.
Our clinical coordinators handle the complete prior authorization paperwork with your insurance company.
Use our online intake form and review treatment-day information before your visit. Contact our team for any additional paperwork or individual preparation instructions.
Complete your medical registration forms at home to allow our team to focus directly on your clinical consultation. We monitor outcomes using PHQ-9 (depression) and GAD-7 (anxiety) metrics before every session.
CLINICAL STUDY REFERENCES
Review standard preparation guidelines including fasting, daily prescription intake coordination, and safety drivers.
Referring clinicians can contact our team for current referral requirements and the appropriate way to share documentation.
Most patients are seen within 24 hours of their initial consultation. We accept major insurance including Aetna, Blue Cross Blue Shield, Cigna, United Healthcare, and Tricare. TMS and Spravato may be covered for qualifying conditions, depending on your insurance and plan; not every plan covers them, and both require prior authorization. Insurance does not cover ketamine infusions, but it may cover your office visit. Complete the form or call us directly – our team will verify your benefits and schedule your first appointment.
Our board-certified team specializes in ketamine infusion therapy, TMS (Transcranial Magnetic Stimulation), and Spravato treatment for depression, anxiety, PTSD, OCD, and chronic pain. We serve patients throughout Northern Virginia from our Fairfax clinic, including McLean, Vienna, Reston, Arlington, Falls Church, and the greater DC metro area.
During your consultation, Dr. Arora will review your medical history, current symptoms, and previous treatments to determine if interventional psychiatry is right for you. We believe in personalized care – no two treatment plans are exactly alike because no two patients are exactly alike.
The Care Clinic is now Resova Health.
A new name and a bold new chapter in mental health care.The name is new. The purpose is not.